Continuing Education Activity

Menstrual-related headaches (MRH) are a common class of headaches that occur in women related to a decline in estrogen during the menstrual cycle. Menstrual-related headaches are related to several important factors, mainly estrogen, which has actions involved in the serotonergic and glutamatergic systems of the CNS. To treat this type of headache, it must be appropriately diagnosed in relation to the menstrual cycle or aligned with exogenous hormones, usually two days before the onset of menses to the third day of menstrual bleeding. This activity reviews the evaluation and treatment of MRH and highlights the role of the interprofessional team in the care of patients with this condition.

Objectives:

• Identify the etiology of menstrual-related migraines.
• Describe the physical exam findings in menstrual-related migraines.
• Review the medical management of menstrual-related migraines.
• Explain the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients with menstrual-related migraines.

Introduction

Menstrual-related headaches (MRH) are a common class of headaches that occur in women related to a decline in estrogen during the menstrual cycle. To treat this type of headache, it must be appropriately diagnosed in relation to the menstrual cycle or aligned with exogenous hormones, usually two days before the onset of menses to the third day of menstrual bleeding. Triptans, nonsteroidal anti-inflammatory drugs (NSAIDs), and hormone therapy are just a few of the many pharmacological interventions used in the management and treatment of menstrual-related headaches.

Etiology

Menstrual-related headaches are related to several important factors, mainly estrogen, which has actions involved in the serotonergic and glutamatergic systems of the CNS. This accounts for its association with headaches, where serotonin and estrogen levels are directly related. During the late secretory phase of the menstrual cycle, when estrogen is low, the production of serotonin decreases, leading to increased calcitonin gene-related peptide (CGRP) and substance P from trigeminal nerves. These substances are involved in the pathophysiology of general migraines and cause vasodilation of intracerebral vessels and sensory sensitization of the trigeminal nerve. Permeability of the blood-brain barrier increases, which releases pro-inflammatory mediators in the pain-sensitive meninges.[1] Around menstruation, cranial nociception is perceived as more intense due to a decrease in endogenous opioid activity, exacerbating the pain pathway.

Family history should be assessed when a patient presents to a provider with a general acute headache. Genetic differences include increased expression of membranous protein channels and receptors involved in the pathophysiology of migraines.[2] These individuals are more susceptible to acute migraine attacks. Other risk factors include those on certain medications, such as combined hormonal contraception. Those who are on higher doses of estrogen are more likely to suffer from MRH due to the acute falls in estrogen during the late luteal and early follicular stages of the menstrual cycle.

Epidemiology

Migraines affect around 12% of the general population and are more frequent in women than men. Peak migraine prevalence in women occurs between the early 30s to early 40s, and menstrual-related headaches are very common in the perimenopausal period, likely due to marked fluctuations in estrogen levels. Up to 41% of all women will have experienced a migraine episode by their early 50s.[3]

Pathophysiology

Increases in sensitivity to pain responses to both central stimuli and peripheral appear to be influenced by estrogen. Estrogen affects the sensitivity of dopaminergic and serotonin receptors and cerebral vessels to serotonin.[4] Activation of central nociceptive pathways from the cortex and brain stem stimulates the trigeminal vascular system, which innervates cerebral blood vessels. This leads to the release of vascular inflammatory substances, including prostaglandins, calcitonin gene-related peptide (CGRP), and cytokines.[5]

History and Physical

Menstrual-related headaches generally present similarly to nonestrogen-related migraines.[6] They frequently have a pulsatile quality, last for about one day, are unilateral, associated with nausea, and can be disabling. Many individuals also report photophobia during attacks, which is relieved by lying down in a dark, quiet room. Menstrual-related headaches should align with the late luteal and early follicular stages of the menstrual cycle, which is a headache between two days before the onset of menses to the third day of menstrual bleeding.

Most patients have a normal neurological exam, but some can experience cutaneous allodynia, which is the perception of pain produced by a small stimulus, such as brushing hair, touching the scalp, shaving, or wearing contact lenses resulting in sensitization of central pain pathways in migraine. Additionally, patients can have tenderness or difficulty resting on the allodynic side. Although rare, some studies suggest migraines can be potential risk factors to cause Bell palsy, sensorineural hearing loss, and oculomotor cranial nerve palsies.[7]

Evaluation

Menstrual-related headaches are mainly a clinical diagnosis. In general radiographic images are relatively normal; however, magnetic resonance imaging (MRI) findings can sometimes have white matter hyperintensities, which have been linked to brain hyperperfusion, breakdown of the blood-brain-barrier, and localized cerebral edema, rather than to primary ischemia. Diffuse non-lateralizing brain hyperperfusion generally prevails during migraine attacks for more than 48 hours in the cerebral cortex, thalamus, and basal ganglia.[8] Radiographic imaging is only warranted when the quality, location, and duration differ from previous headaches.

Migraines cause vasodilation of intracerebral vessels and sensory sensitization of the trigeminal nerve causing inflammatory changes in the pain-sensitive meninges. This results in the permeability of the blood-brain barrier increasing, which releases proinflammatory mediators. Factors to consider when choosing the type of examination depending on the clinical indication, diagnostic performance, availability of computed tomography (CT) or MRI, radiologist expertise, and patient contraindications. Any imaging of the vessels requires the use of IV contrast. Computed tomography angiogram (CTA) and magnetic resonance angiogram (MRA) examinations image both the arteries and veins. MRH should have normal imaging and can sometimes be a diagnosis of exclusion in an emergency medicine setting.

Diagnostic criteria according to International Classification of Headache Disorders, 3rd edition:[9] 

Pure menstrual migraine:

• Attacks in a menstruating woman fulfilling the criteria for migraine without aura
• Attacks occur on days two days before and last till the third day of menstruation

  • Occur in at least 2 out of 3 menstrual cycles
  • Do not occur at other times of the cycle

Menstrually related migraine:

• Attacks in a menstruating woman fulfilling the criteria for migraine without aura
• Attacks occur on days two days before and last till the third day of menstruation

  • Occur in at least 2 out of 3 menstrual cycles
  • Can also occur at other times of the cycle

Treatment / Management

Therapeutic lifestyle measures may be beneficial for controlling migraines, including proper sleep hygiene, healthy nutrition, routine meal schedules, regular exercise, and managing migraine triggers such as stress, alcohol, weather, and, most commonly, hormones.

Managing menstrual-related headaches starts with identifying where the headache aligns with the patient’s menstrual cycle. If a patient is already on oral contraceptive pills (OCPs), the headache may be prevented simply by altering her current hormone regimen by reducing the estrogen dose to limit the premenstrual decline in estrogen that precipitates the MRH.[10][11]

If women are opposed to starting hormonal therapy, are noncompliant, or contraindications exist, common abortive therapy involves using triptans, which target the direct pathophysiologic mechanism of migraines. All triptans are serotonin 1b/1d receptor agonists that prevent pain by blocking trigeminal nerve activation, inhibiting the release of vasoactive peptides, and promoting vasoconstriction.[12][13]

Most nonsteroidal anti-inflammatory drugs (NSAIDs) block COX 1/2 and can be an effective monotherapy in some women. Mefenamic acid has been extensively studied for treating acute MRH and can relieve general dysmenorrhea.[13][14]

Metoclopramide given intravenously has been proven to be as efficacious as triptan therapy when treating acute migraines in an emergency room setting.[15] Akathisia is a potential side effect that can be prevented with diphenhydramine; however, adding diphenhydramine does not improve migraine severity.

Dihydroergotamine is an alpha-adrenergic blocker vasoconstrictor and potent serotonin 1b/1d receptor agonist usually reserved for severe cases of chronic intractable migraine headaches or status migrainosus.[16]

Pharmacologic modulation of CGRP activity appears to mediate trigeminovascular pain transmission in migraine. Calcitonin gene-related peptide (CGRP) antagonists are novel options for acute migraine treatment in patients with either insufficient response or contraindications to first-line medications.[17][18][19]

Other alternative nonpharmacological interventions to consider are nerve blocks. Patients opposed to taking oral or intravenous medications may be candidates for the sphenopalatine ganglion block.[20] This technique involves saturating a long cotton swab in a local anesthetic and inserting the swab into the naris of the unilateral side of the patient’s headache while the patient is in the sniffing position. The swab should be inserted until resistance is met at the posterior wall of the nasopharynx and left in place for at least 10 minutes.

Neuromodulation such as transcutaneous electrical nerve stimulation, single-pulse transcranial magnetic stimulation, and in extreme circumstances, surgical deactivation of migraine trigger sites have limited data but are therapies directed at stimulating the nervous system with an electrical current or a magnetic field. These options are generally reserved for patients with poor response or contraindications to pharmacological interventions.

The use of opioids in treating MRH is generally avoided due to long-term changes in the CNS at the molecular level. Opioids lead to increased descending facilitation from the rostral ventromedial medulla and increased excitatory neurotransmission at the level of the dorsal horn, causing medication overuse headaches.[21] Other data suggests that chronic opioid administration increases CGRP expression in primary afferent neurons upregulating pain afferents.

Differential Diagnosis

Menstrual-related headaches have a broad differential diagnosis, including other primary headaches such as tension and cluster headaches. Treatment of MRH and other primary headaches overlap so that diagnosis can be distinguished from features of the history and physical exam of the patient. Some can experience cutaneous allodynia, which is the perception of pain produced by a small stimulus, such as brushing hair, touching the scalp, shaving, or wearing contact lenses resulting in sensitization of central pain pathways in migraine. These episodes typically last seconds to minutes, but when they increase in intensity and frequency over time, they indicate trigeminal neuralgia, which responds well to a different therapy.

Secondary headaches from trauma, vascular-related injury, metastasis, or infection can also be considered. Cerebral aneurysms, cerebral venous thrombosis, dissection syndromes, encephalitis, meningitis, intracranial hemorrhage, and temporal arteritis will all have different features that can usually be either ruled out or diagnosed with laboratory testing, additional head imaging, or CSF sampling. Since MRH rarely has an association with aura, it is less common to be mistaken for a transient ischemic attack (TIA). Useful features for distinguishing MRH include the duration, timing, quality, comparison to previous headaches, neurological exam, and other associated symptoms during and after the attacks.

Treatment Planning

Table

Aspirin[22] Ibuprofen

Table 1. Acute therapy for migraine

*Adverse effects in this section pertain to all triptans unless specified

Table

Propranolol Metoprolol

Table 2. Preventive therapy for migraine [38]

Prognosis

Women who suffer from menstrual-related headaches generally have a good prognosis, and headaches usually respond well to conventional first-line pharmacological therapy. However, success sometimes depends on the reliability of predicting the regularity of a women’s menstrual cycle. Those with irregular cycles are usually not good candidates for hormone-directed therapy.

Complications

Although triptans are relatively safe drugs, some contraindications do exist. Cardiovascular disease should be screened for hypertension, hypercholesterolemia, smoking history, obesity, diabetes, strong family history of coronary artery disease (CAD), and menopause before initiation of therapy. Prinzmetal angina and CAD are absolute contraindications due to the risk of coronary vasospasm.[39] A complete history of other medications should be taken to avoid possible drug-drug interactions. Patients on antidepressants are at higher risk of developing serotonin syndrome. Chronic exposure to triptans could lead to the downregulation of serotonin receptors and changes in central inhibitory pathways that translate to an impairment of antinociceptive activity and a permanent feeling of head pain.

OCPs should not be given to patients who are older than 35 years and smoke cigarettes, have two or more risk factors for CAD or known ischemic heart valve disease, hypertension, history of venous thromboembolism (VTE), thrombogenic mutations such as antiphospholipid disease or systemic lupus erythematosus (SLE), history of stroke, breast cancer, or migraine with aura.[40] These are all risk factors for hypercoagulability and can ultimately lead to an embolism. Studies have shown that the use of combined hormonal contraceptives among women with migraines with aura is a higher risk of ischemic stroke.[40]

NSAIDs are contraindicated in patients with peptic ulcer disease or at risk for gastroduodenal disease due to blocking prostaglandin, which protects the gastric mucosa. Patients at increased risk of cardiovascular disease may be restricted to NSAID use due to reduced prostaglandin I2 production by vascular endothelium with limited inhibition of prothrombotic platelet thromboxane A2 production, putting patients at higher risk for embolism. Patients with renal disease should avoid NSAID use due to the blockage of prostaglandins, which promote renal vasodilation and maintain renal perfusion.[41]

Deterrence and Patient Education

Patients who experience frequent or severe headaches may benefit from a headache diary over a one-month period where they can record the duration of each headache, the intensity and location, and whether it responded to therapy. Additionally, potential triggers such as food, alcohol, stressors, weather conditions, and what day of their menstrual cycle they are on can be logged. This data may provide information for avoidances and may help to determine what triggers their migraine headaches and what makes them better.

Enhancing Healthcare Team Outcomes

Coordinating care between healthcare professionals is an essential aspect of patient care, especially when modulating a patient's pharmacological therapy. Whether a woman's menstrual headaches are being managed by a neurologist or in the emergency setting, it is important to coordinate with all clinicians. Patients should see the same clinician or, at the very least, a provider in the same health network where other specialists can easily access the electronic medical record. Having old records is an invaluable tool to see if there are any medication regimen changes, history differences, or physical exam findings.

Whether it is a neurologist, an emergency clinician, or another specialist currently treating the patient, improving care coordination with the primary care clinician would minimize adverse effects from new interventions. For example, if a woman with an acute migraine presents, and she does not know that she has an underlying cardiac problem, and she is given triptan therapy, this can lead to fatal coronary vasospasm. Coordinating medication regimens with input from a pharmacist can be a very helpful interprofessional strategy.

Monitoring a patient's headache calendar and coordinating the dates with the patient's menstrual cycle is key to targeting treatment. If there are clear differences in the pattern of quality, location, and timing in the patient's previous recorded headaches, it can suggest an alternate diagnosis. Collaborating care can ultimately change patient management and help identify if the patient needs outpatient therapy versus emergent treatment. Nursing also provides crucial care, coordinating actions between various disciplines and providing necessary patient counseling.

The importance of communication between the interprofessional team cannot be undervalued as patients started on combined hormonal contraception can have serious adverse effects. Patients being treated for acute migraines that have worsened may need to change their long-term treatment regimen but not before clinicians, and other associated healthcare providers coordinate therapies.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Frederiksen SD, Bekker-Nielsen Dunbar M, Snoer AH, Deen M, Edvinsson L. Serotonin and Neuropeptides in Blood From Episodic and Chronic Migraine and Cluster Headache Patients in Case-Control and Case-Crossover Settings: A Systematic Review and Meta-Analysis. Headache. 2020 Jun;60(6):1132-1164. [PubMed: 32293721]

2.

Brunklaus A, Schorge S, Smith AD, Ghanty I, Stewart K, Gardiner S, Du J, Pérez-Palma E, Symonds JD, Collier AC, Lal D, Zuberi SM. SCN1A variants from bench to bedside-improved clinical prediction from functional characterization. Hum Mutat. 2020 Feb;41(2):363-374. [PubMed: 31782251]

3.

Burch R. Epidemiology and Treatment of Menstrual Migraine and Migraine During Pregnancy and Lactation: A Narrative Review. Headache. 2020 Jan;60(1):200-216. [PubMed: 31579938]

4.

Paredes S, Cantillo S, Candido KD, Knezevic NN. An Association of Serotonin with Pain Disorders and Its Modulation by Estrogens. Int J Mol Sci. 2019 Nov 15;20(22) [PMC free article: PMC6888666] [PubMed: 31731606]

5.

Charles A, Brennan KC. The neurobiology of migraine. Handb Clin Neurol. 2010;97:99-108. [PMC free article: PMC5494713] [PubMed: 20816413]

6.

Pescador Ruschel MA, De Jesus O. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 13, 2023. Migraine Headache. [PubMed: 32809622]

7.

Yang CP, Chen YT, Fuh JL, Wang SJ. Migraine and Risk of Ocular Motor Cranial Nerve Palsies: A Nationwide Cohort Study. Ophthalmology. 2016 Jan;123(1):191-7. [PubMed: 26460000]

8.

Hamedani AG, Rose KM, Peterlin BL, Mosley TH, Coker LH, Jack CR, Knopman DS, Alonso A, Gottesman RF. Migraine and white matter hyperintensities: the ARIC MRI study. Neurology. 2013 Oct 08;81(15):1308-13. [PMC free article: PMC3806921] [PubMed: 23975874]

9.

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. [PubMed: 29368949]

10.

Brandes JL. The influence of estrogen on migraine: a systematic review. JAMA. 2006 Apr 19;295(15):1824-30. [PubMed: 16622144]

11.

Calhoun AH. A novel specific prophylaxis for menstrual-associated migraine. South Med J. 2004 Sep;97(9):819-22. [PubMed: 15455962]

12.

Tabeeva GR, Evdokimova EM, Shagbazyan AE. [The efficacy of the second generation triptan migrepam in the treatment of migraine attacks: results of the comparative study]. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(12):20-28. [PubMed: 31994510]

13.

Al-Waili NS. Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo. Eur J Med Res. 2000 Apr 19;5(4):176-82. [PubMed: 10799353]

14.

MacGregor EA. Prevention and treatment of menstrual migraine. Drugs. 2010 Oct 01;70(14):1799-818. [PubMed: 20836574]

15.

Pfaffenrath V, Rehm M. Migraine in pregnancy: what are the safest treatment options? Drug Saf. 1998 Nov;19(5):383-8. [PubMed: 9825951]

16.

Zagami AS. Treatment of the Patient with Refractory Headache. Curr Pain Headache Rep. 2018 Mar 19;22(4):23. [PubMed: 29556828]

17.

Ho TW, Ho AP, Ge YJ, Assaid C, Gottwald R, MacGregor EA, Mannix LK, van Oosterhout WP, Koppenhaver J, Lines C, Ferrari MD, Michelson D. Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Cephalalgia. 2016 Feb;36(2):148-61. [PubMed: 25926620]

18.

Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019 Aug 31;394(10200):737-745. [PubMed: 31311674]

19.

Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019 Jul 11;381(2):142-149. [PubMed: 31291516]

20.

Binfalah M, Alghawi E, Shosha E, Alhilly A, Bakhiet M. Sphenopalatine Ganglion Block for the Treatment of Acute Migraine Headache. Pain Res Treat. 2018;2018:2516953. [PMC free article: PMC5971252] [PubMed: 29862074]

21.

Gunasekera L, Akhlaghi H, Sun-Edelstein C, Heywood J, Sanders L. Overuse of opioids for acute migraine in an Australian emergency department. Emerg Med Australas. 2020 Oct;32(5):763-768. [PubMed: 32270597]

22.

Biglione B, Gitin A, Gorelick PB, Hennekens C. Aspirin in the Treatment and Prevention of Migraine Headaches: Possible Additional Clinical Options for Primary Healthcare Providers. Am J Med. 2020 Apr;133(4):412-416. [PubMed: 31712099]

23.

Lipton RB, Munjal S, Brand-Schieber E, Tepper SJ, Dodick DW. Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache. 2020 Jan;60(1):58-70. [PMC free article: PMC7003821] [PubMed: 31647577]

24.

Wiffen PJ, Knaggs R, Derry S, Cole P, Phillips T, Moore RA. Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults. Cochrane Database Syst Rev. 2016 Dec 27;12(12):CD012227. [PMC free article: PMC6463878] [PubMed: 28027389]

25.

Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst Rev. 2014 May 28;2014(5):CD009108. [PMC free article: PMC6469574] [PubMed: 24865446]

26.

Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD009663. [PMC free article: PMC4164476] [PubMed: 22336867]

27.

Havanka H, Dahlöf C, Pop PH, Diener HC, Winter P, Whitehouse H, Hassani H. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clin Ther. 2000 Aug;22(8):970-80. [PubMed: 10972633]

28.

Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, Earl NL. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology. 1997 Nov;49(5):1210-8. [PubMed: 9371896]

29.

Goadsby PJ, Zanchin G, Geraud G, de Klippel N, Diaz-Insa S, Gobel H, Cunha L, Ivanoff N, Falques M, Fortea J. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008 Apr;28(4):383-91. [PubMed: 18294251]

30.

Smith LA, Oldman AD, McQuay HJ, Moore RA. Eletriptan for acute migraine. Cochrane Database Syst Rev. 2001;(3):CD003224. [PubMed: 11687056]

31.

Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. Headache. 2012 Feb;52(2):292-306. [PubMed: 22309235]

32.

Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA. 2019 Nov 19;322(19):1887-1898. [PMC free article: PMC6865323] [PubMed: 31742631]

33.

Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB., COL MIG-301 Study Group. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018 Dec 11;91(24):e2222-e2232. [PMC free article: PMC6329326] [PubMed: 30446595]

34.

Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019 Jul 01;142(7):1894-1904. [PMC free article: PMC6620826] [PubMed: 31132795]

35.

Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD^® ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Headache. 2021 Sep;61(8):1214-1226. [PMC free article: PMC9292844] [PubMed: 34363701]

36.

Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ. 2010 Apr 20;182(7):E269-76. [PMC free article: PMC2855933] [PubMed: 20159899]

37.

Markley HG. Verapamil and migraine prophylaxis: mechanisms and efficacy. Am J Med. 1991 May 17;90(5A):48S-53S. [PubMed: 2039020]

38.

Modi S, Lowder DM. Medications for migraine prophylaxis. Am Fam Physician. 2006 Jan 01;73(1):72-8. [PubMed: 16417067]

39.

Mathew PG, Klein BC. Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk. Headache. 2019 Sep;59(8):1421-1426. [PubMed: 31318457]

40.

Champaloux SW, Tepper NK, Monsour M, Curtis KM, Whiteman MK, Marchbanks PA, Jamieson DJ. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017 May;216(5):489.e1-489.e7. [PubMed: 28034652]

41.

Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005 Mar;45(3):531-9. [PubMed: 15754275]

Disclosure: Gregory Moy declares no relevant financial relationships with ineligible companies.

Disclosure: Vikas Gupta declares no relevant financial relationships with ineligible companies.